The compound, designated GL60667, is the second Genelabs non-nucleoside compound to advance into preclinical development. Genelabs has also further advanced GL59728, its first non-nucleoside preclinical development candidate. Genelabs
The expansion of the trial sees the initiation of studies in two new centers; these are Princess Margaret Hospital in Toronto, Canada, and Jewish General Hospital in Montreal.
The phase I study demonstrated the ability of ISIS 301012 to produce rapid reductions of its target, apoB-100, with concomitant reductions in low density lipoprotein (LDL or “bad”
This round of the funding includes $4.4 million from the National Institute of Allergy and Infectious Diseases (NIAID) and $1 million from the Department of Defense (DoD). To
The Belgian research institute and Acambis will work together to develop a vaccine against both A and B strains of influenza, using Acambis’ influenza A vaccine candidate that
The study, involving 28 subjects with plaque psoriasis, was designed to evaluate the local and systemic safety of CTA018. Results of the study indicate that the drug is
Mumbai-based TCS has won a contract with Congenia, a start-up subsidiary of Italian biotech company Genextra SpA, to provide software that will help Congenia with its research into
The main objectives of these studies are to evaluate safety, treatment duration, patient populations and a range of doses that will be incorporated into phase III pivotal trials.
The first investigation to be undertaken will aim to improve the understanding and management of sepsis and community acquired pneumonia (CAP). This multi-year project is expected to further
Researchers found that all of the brains of dementia patients showed quinolinic acid neurotoxicity. This acid kills nerve cells in the brain, leading to brain dysfunction and ultimately
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.